Mechanistically, IFN-β increases tumor antigen cross-presentation to activate potent T cell- and NK cell-mediated antitumorigenic effects (repressed tumor growth and metastases) while inhibiting immunosuppressive cells including MDSCs and Tregs. This evidence concerns the gene IFNB1 and neoplasm.